Apr 24, 2025
Antibody-drug conjugates (ADCs) are novel therapeutic agents designed to target specific tumor markers with potent anticancer drugs. The Association of Cancer Care Centers (ACCC) is dedicated to providing up-to-date information on ADC treatment management. In this episode, CANCER BUZZ speaks with Nancy Mallett, a patient advocate, to discuss the patient’s perspective and experience receiving treatment for gynecologic cancers, particularly with ADCs such as mirvetuximab soravtansine-gynx.
“[Providers] giving me the information and allowing us to decide together, instead of just telling me, makes me feel more cared about and that I’m not just a number, I’m a person. They care about what I think, and look at my life and what it can do for me.” – Nancy Mallett
Nancy Mallett
Patient Advocate
Resources:
FDA Approval Summary: Mirvetuximab soravtansine-gynx for FRα-positive, Platinum-Resistant Ovarian Cancer - https://bit.ly/4is00nD
Society of Gynecologic Oncology (SGO): Gynecologic Cancer Resources for Patients and Their Families - https://bit.ly/4jpYaoP
ASCO: Antibody-Drug Conjugates in Gynecologic Cancer - https://bit.ly/42GP5k8
Society of Gynecologic Oncology Journal Club: The ABCs of ADCs (Antibody drug Conjugates) - https://bit.ly/42U2962
Antibody-Drug Conjugates in Gynecologic Cancers - https://bit.ly/4cLYECZ
Funder Statement
This program is supported by AbbVie.